Parallel reaction monitoring (PRM) and multiple reaction monitoring (MRM, also called selected reaction monitoring, SRM) are both targeted methods for a closed peptide list. They do not replace data-dependent acquisition (DDA) or data-independent acquisition (DIA) discovery. MRM on a triple quadrupole quantifies predefined precursor-to-product transitions. PRM on a quadrupole-Orbitrap or quadrupole-time-of-flight instrument isolates scheduled precursors and records a full high-resolution fragment spectrum, so quantitative ions can be chosen after acquisition. Prefer PRM when early method refinement and accurate-mass fragment review matter in complex matrices. Prefer MRM when a mature transition panel must run at very high multiplex. Absolute amount requires a matched stable isotope-labeled standard (SIS) in either route. PRM and MRM/SRM are important targeted acquisition strategies within quantitative proteomics workflows. For a broader overview of targeted quantitative proteomics principles, workflow design, and application scenarios, see Targeted Quantitative Proteomics: Principles, Strategies, and Applications.
Researchers who already have a closed peptide panel or a specific validation objective can also review the MtoZ Biolabs Parallel Reaction Monitoring (PRM) Service for project-specific feasibility and assay planning.
What PRM and MRM Each Record
MRM monitors chosen transitions through a triple-quadrupole path: Q1 isolates the precursor, the collision cell fragments it, and Q3 passes selected product ions for detection. The dataset is compact and transition-centric. Method development centers on picking clean transitions before the cohort is queued.
PRM isolates a scheduled precursor and records all product ions in one high-resolution MS2 event (Peterson et al. 2012). Quantitative and qualifier fragments are extracted afterward, commonly in Skyline-class software. That design shortens early transition locking and helps when unit-resolution interference is a concern. The isolation window is still a window in both methods, so co-isolated ions can remain a limit.
Figure 1. MRM records selected transitions; PRM stores a full high-resolution fragment spectrum for each scheduled precursor and extracts peak areas after the run.
Both assays measure only scheduled targets; recording all fragments of a precursor is not the same as surveying the whole proteome.
Side-by-Side Comparison for Method Selection
|
Dimension |
MRM / SRM |
PRM |
|---|---|---|
|
Instrument |
Triple quadrupole |
Quadrupole-Orbitrap or Q-TOF |
|
Pre-run setup |
Precursor-product transitions |
Precursor list and retention-time schedule |
|
Fragment information |
Selected transitions only |
Full high-resolution MS2 |
|
Specificity lever |
Transition uniqueness at unit resolution |
Accurate-mass fragment discrimination |
|
Method development |
Transition optimization is central |
Fragment choice can continue during review |
|
Multiplex tendency |
High when transitions are short and mature |
Limited by MS2 fill time and scan cycle |
|
Typical fit |
Mature high-throughput panels |
Complex-matrix validation and panel refinement |
No row is an absolute ranking for every sample. Sensitivity and throughput depend on peptide ionization, chromatography, dwell or fill time, and matrix background. Saying PRM always replaces MRM, or that MRM is always more sensitive, overstates what the instrument class alone decides.
Figure 2. PRM and MRM share a closed-list targeted claim; they differ mainly in what is recorded and how multiplex and fragment review are traded.
Judgment Criteria: When to Choose PRM, MRM, or a Sequence of Both
Choose PRM when the panel is still being refined, the matrix is complex, and inspectors need to drop or replace fragments after seeing the spectrum. Choose MRM when transitions are already validated and the limiting need is running a large scheduled panel efficiently on a triple quadrupole. A common research sequence is discovery by DDA or DIA, confirmation of a short list by PRM, and, if needed later, transfer of a locked transition set to MRM for broader cohort throughput. That sequence is a project plan, not a rule that every study must follow.
|
Study need |
Prefer PRM |
Prefer MRM |
|---|---|---|
|
Target status |
Short list still under fragment review |
Locked transition panel |
|
Matrix challenge |
Accurate-mass discrimination helpful |
Clean, mature transitions already work |
|
Throughput pressure |
Moderate panel size acceptable |
Very high multiplex is required |
|
Infrastructure |
High-resolution targeted platform available |
Triple quadrupole is the production platform |
|
Claim type |
Relative confirmation; absolute with SIS |
Relative confirmation; absolute with SIS |
Figure 3. Selection follows whether the assay still needs inspectable high-resolution fragments or already has a mature transition panel for high multiplex.
Researchers who need a PRM-centered workflow walkthrough can refer to Parallel Reaction Monitoring (PRM): Principles, Workflow, and Applications for operational steps beyond the comparison table.
Limits and Application Boundaries
Shared limits
Neither method recovers proteins outside the inclusion list. Shared peptides create gene-family ambiguity. Digestion or enrichment failure upstream of an SIS spike remains invisible to detector resolution. Relative peak areas are the default claim; absolute concentration needs matched SIS peptides and a stated calibration model.
Application contexts
Both methods are used for biomarker candidate validation, pathway-protein panels, pharmacodynamic time courses, and selected modified-peptide checks when discriminating ions can be defined. PRM is often used earlier in complex matrices when fragment evidence must be reviewed. MRM is often used when a hospital or pharmaceutical laboratory already runs a mature triple-quadrupole panel at scale. Diagnostic cutoffs and clinical decision rules sit outside ordinary research reporting unless a separately validated assay framework is in place.
Cost and instrument access matter operationally. Triple quadrupoles are widely deployed for routine MRM. Orbitrap- or Q-TOF-based PRM usually has higher capital and maintenance burden. Access explains feasibility; it does not by itself decide which scientific claim is correct.
Once the peptide list, relative-versus-absolute design, and multiplex needs are defined, the project can be evaluated as a targeted PRM or MRM study. Researchers can review the MtoZ Biolabs Parallel Reaction Monitoring (PRM) Service for sample evaluation, panel feasibility, and workflow planning.
Frequently Asked Questions
1. Is PRM simply better than MRM?
No. PRM improves post-acquisition fragment choice and accurate-mass discrimination. MRM remains strong for mature, high-multiplex transition panels on triple quadrupoles.
2. Can either method replace DDA or DIA discovery?
No. Both require a closed target list. Keep discovery acquisition while new protein names are still needed.
3. Do PRM and MRM both support absolute quantification?
Yes, when matched SIS peptides and a calibration model are included. Without SIS, the default claim is relative.
4. Why does PRM method development often look faster?
Because quantitative fragments can be selected from stored high-resolution MS2 spectra. Precursors and retention-time windows must still be scheduled correctly.
5. Can the two methods be used in one project?
Yes. A short list may be confirmed by PRM and later transferred to MRM if a locked transition panel must run at higher multiplex. Report each stage with its instrument and transition or fragment rules.
Reference
- A.C. Peterson, J.D. Russell, D.J. Bailey, M.S. Westphall, J.J. Coon (2012). Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol. Cell. Proteomics, 11, 1475-1488. https://doi.org/10.1074/mcp.O112.020131
- V. Lange, P. Picotti, B. Domon, R. Aebersold (2008). Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol., 4, 222. https://doi.org/10.1038/msb.2008.61
